The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Forxiga (EMA)
Diabetes News
Tag: EMA
Ozempic (semaglutide)
On 14 December 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ozempic, intended for the treatment of type 2 diabetes. The applicant for this medicinal product is Novo Nordisk A/S (European Medicines Agency)
Toujeo® Receives Positive Opinion from the European Regulatory Authorities
Sanofi announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL)
Glycosmedia is also available as an App: